Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is getting ridiculous to watch
Another disappointing day
Disappointing
Not too thrilled to see the increase in authorized and conditional share capital. Unless they are getting ready to uplist why would conditional shares increase so much?? Blocking hostile takeovers?…or is it just straight dilution or covering the loss they are carrying forward?
This really is and is not about Covid. This, when given EUA, also validated it’s capable of being used for ARDS, lung disorders, and other disease that effects the body
Maybe. The FDA did work directly with us on data, locations, number of patients, etc. I am not sure they would have done a comparison study with our drug if they had concerns
It essentially shows why CYDY got hammered just about 25 mins ago. Their trials did not follow this structure. Reminder here, RLFTF/NRX have been working with FDA the entire time. I don’t think we should be concerned
A lot of us could argue the same points about your posts…
Nephron pharmaceuticals
Enough already. You bring little value with your loudspeaker broadcasting….
From the S-4 filing:
“NeuroRx anticipates delivering the detailed efficacy and safety data requested by FDA for an EUA determination by the end of May 2021 in the eCTD electronic format required by FDA and all regulators who are parties to the International Commission on Harmonization (ICH-10). If NeuroRx meets this objective, it will have delivered a regulatory file delineating safety and efficacy data of an investigational drug within 3 months of last visit in a clinical trial. Although there can be no assurance that the FDA will conclude that ZYESAMI meets or exceeds the EUA standard of “may be effective” in the treatment of COVID-19, NeuroRx is hopeful that the FDA will grant EUA to ZYESAMI."
Very disappointed to see all this
You two have issues
I understand but we need some buying interest to make all of what you say here matter.
Sorry but the price keeps going down so that really doesn’t matter at all.
Look, the only thing here in debate is the issue with the patent. Relief owns the patent on the formulation of Aviptadil. NeuroRX has trademarked that formulation as Zyesami. However that only is done to protect the name and selling of the formulation that Relief still owns the patent to. This is all marketing and nothing more. At the end of the day, the formula is owned by Relief, and the variation of formula is patent protected for Relief. All NRX can do is create the naming for sales. Profit sharing across the globe has already been agreed to.
Look, the only thing here in debate is the issue with the patent. Relief owns the patent on the formulation of Aviptadil. NeuroRX has trademarked that formulation as Zyesami. However that only is done to protect the name and selling of the formulation that Relief still owns the patent to. This is all marketing and nothing more. At the end of the day, the formula is owned by Relief, and the variation of formula is patent protected for Relief. All NRX can do is create the naming for sales. Profit sharing across the globe has already been agreed to.
For all those wondering WHY there is nothing to worry about when it comes to this SUNY licensing nonsense....here you go:
Formulation patent
This claims the pharmaceutical dosage form on the drug, commonly also known as a composition but not to be confused with ‘composition of matter’ (see previously). It may take the form of a formulation of a particular drug or class of drugs, or a general formulation applicable to many drugs with different actions, such as slow release technologies, transdermal patches, etc. There may also be formulation process patents covering the manufacturing processes used to make the formulation.
State university of New York....idiots.
Aviptadil = Zyesami = RLF-100
Neuro runs Zyesami and gains 50% of the revenues in the US and Israel.
Relief runs RLF-100 and gains 85% of the revenues in Europe and rest of the world.
Neuro gains recognition first for running the trial and obtaining FDA approval. EUA starts the first revenue stream and it is split 50/50.
Next Relief gains approval in Europe and ROW for an even bigger slice of the pie.
We all get paid and we all win.
It is all in the recent S4 filing....
More fun today I see...
NIH Press release, from today, with Fauci even acknowledging Zysesami/Aviptildl...they are well aware. I feel EUA is coming in April
https://www.nih.gov/news-events/news-releases/clinical-trial-therapeutics-severely-ill-hospitalized-covid-19-patients-begins
We just gave ACER $4M...pay and move on Ram!
Another day of pain it looks like unfortunately
Understand that, but they aren’t taking advantage of other avenues to promote this either. Social media is easy and effective as a marketing tool. It got a president elected, in part, and is highly influential
Social media is free! They would only need to pay a lawyer to review a post which is basically nothing
Par for the course
Javitt was just on Fox Business!!!
Well I guess it wasn’t the stock apparently
About to jump??
Inhaled study update :)
https://clinicaltrials.gov/ct2/show/record/NCT04360096?view=record
My god, am I sick of pre-market BS. This team needs to start getting press out there
Wait you mean to tell me that companies other than this one and their partner don’t spin their data??? Seriously stop it.
The end of the day is like flies on crap. Flies fly up and then back down to the crap they were on. Would be good to see something pin the manipulation on its heels here
Get some press going already. This is aggravating
Not what I was hoping for but let’s see what EUA can do for us, if granted.
The real play here now is to hold until EUA is given. Could be this week, easily!
Amazing. Truly hope you’re right. That might blow the lid off
Dr Javitt: “We look forward to working with the National Institutes of Health, the Department of Defense, the FDA, and regulators around the world to bring this treatment to patients as quickly as possible."
THIS RIGHT HERE!!